Farhad Ravandi

Decitabine improves patient outcomes in myelodysplastic syndromes

Hagop M. Kantarjian, Jean‐Pierre J. Issa, C Rosenfeld et al. · Cancer · 2006 · 1.5K citations

Medicine, Hematology, Pharmacology +14

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele et al. · Blood · 2021 · 718 citations · Full text

Medicine, Hematology, Oncology +17

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Hagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia‐Manero et al. · Blood · 2006 · 689 citations · Full text

Medicine, Oncology, Pharmacology +16

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud et al. · Journal of the National Comprehensive Cancer Network · 2017 · 655 citations · Full text

Medicine, Hematology, Oncology +16